News
CRMD
8.57
-3.38%
-0.30
Cormedix (CRMD) Gets a Buy from RBC Capital
TipRanks · 19h ago
CorMedix Inc. to Join Nasdaq Biotechnology Index Effective December 23, 2024
Barchart · 1d ago
CorMedix Is Maintained at Outperform by RBC Capital
Dow Jones · 1d ago
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $12
Benzinga · 1d ago
CorMedix set to join Nasdaq Biotechnology index
Seeking Alpha · 1d ago
*CorMedix Added to Nasdaq Biotechnology Index
Dow Jones · 1d ago
CorMedix Inc. Added to Nasdaq Biotechnology Index, Effective Prior To The Market Open On Monday, December 23, 2024.
Benzinga · 1d ago
CorMedix price target raised to $12 from $11 at RBC Capital
TipRanks · 2d ago
U.S. RESEARCH ROUNDUP-Amazon, Mastercard, Tesla
Reuters · 2d ago
CORMEDIX INC <CRMD.O>: RBC RAISES TARGET PRICE TO $12 FROM $11
Reuters · 2d ago
Weekly Report: what happened at CRMD last week (1209-1213)?
Weekly Report · 5d ago
Weekly Report: what happened at CRMD last week (1202-1206)?
Weekly Report · 12/09 10:50
Weekly Report: what happened at CRMD last week (1125-1129)?
Weekly Report · 12/02 10:50
CorMedix Inc. Commends CMS Policy Changes Expanding Access to Innovative Therapies for Hemodialysis Patients
Barchart · 11/26 17:52
CorMedix Set for Market Growth with Policy Changes and Strategic Partnerships Boosting DefenCath Adoption
TipRanks · 11/26 15:05
CorMedix supports CMS policy updates
TipRanks · 11/26 13:40
CorMedix Approves Key Governance and Incentive Changes
TipRanks · 11/25 21:50
Weekly Report: what happened at CRMD last week (1118-1122)?
Weekly Report · 11/25 10:44
Weekly Report: what happened at CRMD last week (1111-1115)?
Weekly Report · 11/18 10:42
Weekly Report: what happened at CRMD last week (1104-1108)?
Weekly Report · 11/11 10:52
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.